04/18/2022
Three Steps Further
What does it take to make sure localized prostate cancer never comes back? A new Phase II clinical trial aims to find out, and it is noteworthy in two ways: One, as its principal investigator, medical oncologist Fatima Karzai, M.D., puts it, “We’re being aggressive in treating high-risk disease.” And. Read More
04/14/2022
Healthy Eating On the Go: Do the Best You Can
We get a lot of questions about what to eat when you’re traveling, or when you’re at an event and don’t have a lot of healthy options. During the pandemic, there has been less travel and fewer parties, but as we emerge from each new wave, we may encounter more. Read More
04/04/2022
What is National Minority Health Month?
National Minority Health Month is observed each year in April to raise awareness of health disparities among racial and ethnic minority communities and spur action to overcome these injustices. The origin dates back to 1915, when Black educator and leader Booker T. Washington launched National Health Improvement Week (later National. Read More
03/29/2022
Highlights of ASCO GU 2022, Part 2
Informing care for intermediate-risk cancer, a new imaging tracer, and understanding the effects of PSA screening recommendations Clinicians and researchers gathered last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) — some in-person in San Francisco, some tuning in virtually. Hundreds of presentations covered advances. Read More
Prostate Cancer Patient Guide
PCF's Prostate Cancer Patient Guide is compiled with the contributions of top-tier doctors and researchers in prostate cancer, and is a must-have resource for patients and families. It focuses all of the information available about contemporary prostate cancer research, treatment, and lifestyle factors into one consolidated document. It is for. Read More
03/23/2022
Breaking News: First-in-Class Radioligand Therapy Approved for Advanced Prostate Cancer
What this means for patients: Today, a new treatment known as 177lutetium-PSMA-617 (Lu-PSMA; trade name Pluvicto®) was approved by the FDA for certain patients with advanced prostate cancer. This medicine delivers a small dose of radiation attached to a molecule that specifically binds to prostate cancer cells. It has been shown to. Read More
How PCF is Furthering Health Equity and Combating Prostate Cancer Disparities
In the U.S., 1 in 8 men in their lifetime will be diagnosed with prostate cancer. But the disease does not affect all men equally. 1 in 6 Black men will be diagnosed with prostate cancer in their lifetime and they are more than 2 times as likely to die. Read More
03/22/2022
Roasted Spring Brussels Sprouts
It’s spring. That means the grocery stores will begin to fill with a glorious abundance of seasonal fruits and vegetables. For some, April also means a family gathering filled with traditional Easter dishes and Easter bunny treats. Whether you celebrate Easter or just worship the leaves and flowers popping through. Read More
03/21/2022
Guía para pacientes con cáncer de próstata | Prostate Cancer Patient Guide
La guía más reciente de la Fundación contra el Cáncer de Próstata es para pacientes que prefieren leer en español. Se basa en nuestra guía completa para pacientes con cáncer de próstata, compilada con las contribuciones de médicos e investigadores expertos, y en nuestra guía para la salud y el. Read More
03/15/2022
Millions in New Federal Funding for Prostate Cancer Research
Today President Biden signed into law H.R. 2471, the “Consolidated Appropriations Act, 2022”, which was passed by the House and Senate last week. The omnibus package notably includes: $110 million for the Peer-reviewed Prostate Cancer Research Program at the Department of Defense $14.2 million for Prostate Cancer at the Centers. Read More